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Edited by Robert BaroukiAbstract Dipyrithione (PTS2) possesses anti-bacterial and
anti-fungal activity. In the present study, we found that PTS2
dose-dependently inhibited the LPS-induced up-regulation of ni-
tric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) pro-
tein level in RAW264.7 cells. RT-PCR experiments showed that
PTS2 suppressed LPS-induced iNOS but not COX-2 expression
at the mRNA level. As expected, PTS2 prevented NO secretion
in RAW264.7 cells. Furthermore, PTS2 administration signiﬁ-
cantly decreased LPS-induced mortality in mice. Mechanisti-
cally, PTS2 decreased expression and phosphorylation of
STAT1, but did not interfere with the MAPK and NF-jB path-
ways. In conclusion, PTS2 protects mice against endotoxic
shock and inhibits LPS-induced production of pro-inﬂammatory
mediators, suggesting that PTS2 could play an anti-inﬂamma-
tory role in response to LPS.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Lipopolysaccharide (LPS), a constituent of the gram-nega-
tive bacterial cell wall, induces inﬂammatory responses when
administered to cells or animals, which is similar to those seen
in septic shock, a serious circulatory disorder with a high mor-
tality rate of 30–90% [1], indicating an apparent ineﬃciency of
its current treatment [2,3]. Pro-inﬂammatory cells, mainly acti-Abbreviations: PTS2, dipyrithione; LPS, lipopolysaccharide; iNOS,
inducible nitric oxide synthase; NO, nitric oxide; COX-2, cyclooxy-
genase-2; STAT1, signal transducers and activators of transcription 1;
MAPKs, mitogen-activated protein kinases; NF-jB , nuclear factor
jB; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal
kinase
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doi:10.1016/j.febslet.2008.04.016vated macrophages, are responsible for most of the cellular
and molecular pathophysiology of sepsis by producing cyto-
kines and other pro-inﬂammatory molecules including plate-
let-activating factor, prostaglandins, enzymes, and free
radicals, such as nitric oxide (NO) [4–6]. Among a variety of
inﬂammatory mediators, two of the most prominent are nitric
oxide (NO) produced by inducible NO synthase (iNOS) and
prostaglandins by cyclooxygenase-2 (COX-2; prostaglandin
H2 synthase) [7,8]. NO may regulate almost all stages in the
development of inﬂammation, in particular, the early stages
of inﬂammatory cell transmigration to the sites of inﬂamma-
tion [9]. Prostaglandin E2 (PGE2), the production of COX-2,
works as a common ﬁnal mediator of the febrile [10]. Previous
reports showed that when iNOS was up-regulated in inﬂam-
matory cells, COX-2 expression increased in a similar pattern
[11], suggesting the interaction between iNOS and COX-2. Re-
cently, it is reported that NO up-regulates COX-2 expression
and iNOS binds, s-nitrosylates and activates COX-2 [12,13].
In various cells including macrophages, LPS stimulates toll-
like receptor 4 (TLR4) to activate nuclear factor jB (NF-jB)
that is an important transcription factor for iNOS and COX-
2 [14]. LPS also had been shown to activate mitogen-activated
protein kinases (MAPKs) pathways to enhance iNOS and
COX-2 gene expression in macrophages [15–17]. Another tran-
scription factor, the signal transducer and activator of tran-
scription 1 (STAT1), is involved in LPS-induced iNOS
expression, which is activated through the Janus kinase
(JAK)–STAT-pathway [18,19].
Dipyrithione (2,2 0-dithiobispyridine-1,1 0-dioxide, PTS2)
(CAS number: 3696-28-4), a pyrithione derivate (Fig. 1), is
usually used as anti-bacterial and anti-fungal drug. Pyrithione
(PTO), the monomer of PTS2, which inhibits the growth of
fungi, yeast, mold, and bacteria, is widely used in cosmetics
and shampoo. Recently, we reported that PTS2 induced HeLa
cells apoptosis through activating MAPKs pathway [20]. Here,
we show the evidence that PTS2 inhibits LPS-induced up-reg-
ulation of iNOS and COX-2 protein levels in RAW264.7 cells
and protects mice against endotoxic shock. We also found that
LPS-induced increase of iNOS but not COX-2 mRNA level
was suppressed signiﬁcantly by PTS2 treatment. This diﬀer-
ence between the regulation eﬀects of PTS2 on iNOS and
COX-2 is related with the mechanism that PTS2 preventsblished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structure of PTS2.
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strongly suggest that PTS2 might exert anti-inﬂammatory
activities in LPS-induced inﬂammation.2. Materials and methods
2.1. Antibodies and reagents
Polyclonal antibodies against JNK/SAPK, phospho-JNK/SAPK (p-
JNK), p38 MAPK, phospho-p38 MAPK (p-p38), ERK, phospho-
ERK (p-ERK), IjB-a, phospho-IjB-a (p-IjB-a) and phospho-STAT1
(p-STAT1 Y701) were obtained from Cell Signaling Technology. Anti-
body to STAT1 and COX-2 were from Santa Cruz Biotechnology. The
iNOS monoclonal antibody was purchased from BD Pharmingen. All
secondary antibodies used for Western blotting were purchased from
Calbiochem. LPS (from Escherichia coli 0111: B4) was purchased from
Sigma. PTS2 was purchased from J&K Chemical Ltd.
2.2. Cell culture
RAW264.7, a murine macrophage-like cell line purchased from the
CBCAS (Cell Bank of the Chinese Academic of Sciences, Shanghai,
China) was maintained in Dulbeccos modiﬁed Eagles medium (Invit-
rogen) supplemented with 10% (v/v) fetal bovine serum (Hyclone) and
antibiotics (100 U/ml penicillin and 100lg/ml streptomycin) (Hy-
Clone) at 37 C in an atmosphere of 5% CO2.
2.3. Western blotting
Cells were rinsed twice with ice-cold PBS, and solubilized in lysis
buﬀer containing 20 mM Tris (pH 7.5), 135 mM NaCl, 2 mM EDTA,
2 mM DTT, 25 mM b-glycerophosphate, 2 mM sodium pyrophos-
phate, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate,
10 mM NaF, 10 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM phen-
ylmethylsulfonyl ﬂuoride (PMSF) for 30 min. Lysates were centrifuged
(15000 · g) at 4 C for 15min. Equal amounts of the soluble protein
were denatured in SDS, electrophoresed on a 12% SDS–polyacryl-
amide gel, and transferred to a PVDF membrane. The immunoblotting
were performed as described [21]. The horseradish peroxidase (HRP)-
conjugated goat anti-mouse or anti-rabbit IgG antibodies were used
against respective primary antibody. The proteins were visualized
using Lumi-Light Western Blotting Substrate (Roche Molecular Bio-
chemicals).
2.4. Reverse transcriptase-PCR (RT-PCR)
Total RNAwas extracted with Trizol reagent (Gibco) as described by
the manufacturer. RT-PCR was performed by Access RT-PCR System
kit (Promega) according to the protocol with indicated primers (iNOS:
sense primer 5 0-cccttccgaagtttctggcagc-30, antisense primer 5 0-ggctgtca-
gagcctcgtggctt-3 0; COX-2: sense primer 5 0-tctccaacctctcctactac-3 0,
antisense primer 5 0-gcacgtagtcttcgatcact-3 0; GAPDH: sense primer
5 0-tgaaggtcggtgtgaacggatttggc-3 0, antisense primer 5 0-tggttcacacccatca-
caaacatgg-30). PCR was performed for 30 cycles in 25 ll of reaction
mixture. PCR products were visualized in 1.2 % agarose gels stained
with EtBr. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was utilized as a housekeeping gene where indicated.
2.5. Nitrite analysis
NO synthesis was spectrophotometrically determined by assaying
the culture supernatants for nitrite using the Griess reagent (1% sulfa-
nilic acid, 0.1% N-1-naphthyl-ethylenediamine dihydrochloride, and5% phosphoric acid). Absorbance was measured at 550 nm and nitrite
concentration was determined using sodium nitrite as a standard.2.6. Endotoxin shock model of mice
Male ICR mice weighing 18–22 g were purchased from Shanghai
Experimental Animal Center, China Academy of Science. Laboratory
animal handling and experimental procedures were performed in
accordance with the requirements of Provisions and General Recom-
mendation of Chinese Experimental Animals Administration Legisla-
tion and were approved by Science and Technology Department of
Jiangsu Province. Each mouse was i.p. injected with LPS (37.5 mg/
kg) in saline. Thirty minutes after LPS challenge the mice were admin-
istrated (i.p) with saline, PTS2 (1, 2.5 and 5.0 mg/kg) or dexametha-
sone (2 mg/kg), respectively. The survival rates were monitored
continuously for 4 days.2.7. Statistics
Analysis of variance (ANOVA) was used to compare the results be-
tween two groups. Individual points were compared using a Students t
-test and diﬀerences were considered signiﬁcant for P < 0.05. Data are
presented as means ± S.D. Western blotting analysis experiments were
repeated 2–3 times with similar trends.3. Results
3.1. PTS2 inhibits LPS-induced up-regulation of iNOS and
COX-2 in RAW264.7 cells
iNOS and COX-2 are two of the inﬂammatory factors which
are correlated with LPS stimulation. To investigate the anti-
inﬂammatory activity of PTS2, we tested the eﬀects of PTS2
on LPS-induced iNOS and COX-2 protein up-regulation in
RAW264.7 cells by Western blotting. The cells were incubated
for 8.5 h with 1.0–5.0 lM PTS2 30 min after LPS (100 ng/ml)
pretreatment. The results showed that LPS-induced cellular
iNOS and COX-2 protein increased dramatically and PTS2
inhibited the elevation of iNOS and COX-2 level in a dose-
dependent manner. PTS2 alone even at concentration of
5.0 lM did not inﬂuence iNOS and COX-2 protein level in
normal RAW264.7 cells (Fig. 2A). Aspirin is an aceylated
salicylate used to treat inﬂammation and arthritis pain and
has been reported to modulate LPS-induced NO release [22].
As shown in Fig. 2B, though 3 lM of both PTS2 and Aspirin
inhibited LPS-induced iNOS and COX-2 expression eﬀec-
tively, PTS2 exhibited stronger inhibitory ability than Aspirin.
In comparing PTS2 with its monomer, PTO, we found that
PTS2 also acted more eﬀective in inhibiting LPS-induced iNOS
and COX-2 expression than PTO (Fig. 2C).
3.2. The eﬀects of PTS2 on LPS-induced increase of iNOS and
COX-2 mRNA level
As above results indicated that PTS2 inhibited the increase
of iNOS and COX-2 protein level induced by LPS, we then
performed RT-PCR to analyze the eﬀects of PTS2 on LPS-in-
duced iNOS and COX-2 expression at mRNA level.
RAW264.7 cells were pretreated with LPS (100 ng/ml) for
30 min or not, and then incubated with 3.0 lM PTS2 for
8.5 h. Total RNA were isolated, iNOS and COX-2 mRNA
was determined by RT-PCR. As shown in Fig. 3, LPS stimu-
lation elevated endogenous mRNA level of iNOS and COX-
2, whereas PTS2 suppressed LPS-induced increase of iNOS
but not COX-2 mRNA level. These data suggested that
PTS2 aﬀected iNOS and COX-2 protein level through diﬀerent
route.
Fig. 2. The eﬀects of PTS2 on LPS-induced increase of iNOS and COX-2 protein level in RAW264.7 cells. Western blot was performed using
antibodies to iNOS, COX-2 and GAPDH. (A) RAW264.7 cells were pretreated with LPS (100 ng/ml) for 30 min or not, and then incubated with 1.0–
5.0 lM PTS2 for 8.5 h. Cell lysates were prepared and subjected to Western blot. (B) The cells were pretreated with LPS (100 ng/ml) for 30 min or
not, and then incubated with 3.0 lM PTS2 or Aspirin for 8.5 h. (C) Cells were pretreated with LPS (100 ng/ml) for 30 min or not, followed by
incubating with 3.0 lM PTS2 or PTO for 8.5 h. The results were representative of three independent experiments.
Fig. 3. The eﬀects of PTS2 on LPS-induced rise of iNOS and COX-2
mRNA levels in RAW264.7 cells. Cells were pretreated with LPS
(100 ng/ml) for 30 min or not, followed by incubating with 3.0 lM
PTS2 for 8.5 h. Total RNA were isolated, iNOS and COX-2 mRNA
were determined by RT-PCR. GAPDH mRNA was used as control.
The results were representative of three independent experiments.
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up-regulation in RAW264.7 cells
We also detected duration of the anti-inﬂammatory activity
of PTS2 in RAW264.7 cells. The cells were incubated with LPS
(100 ng/ml), 3.0 lM PTS2 or both of them for 0–14 h, andthen the cell lysates were subjected to Western blot analysis
by using anti-iNOS antibody. As shown in Fig. 4A, LPS
aroused a signiﬁcant increase in iNOS protein level 8 h and
14 h after LPS treatment and PTS2 (3.0 lM) displayed more
eﬀective in inhibiting LPS-induced iNOS up-regulation at 8 h
than 14 h time point after LPS treatment.
To evaluate the best time course of administration, we tested
the eﬀects of PTS2 on LPS-induced iNOS expression at four
time points when PTS2 was administrated 0.5, 1, 2 and 4 h
after LPS stimulation. The result from Western blot analysis
showed that PTS2 inhibited LPS-induced up-regulation of
iNOS protein at all time points and acted better when it was
administrated with cells at 0.5 h than 1, 2 or 4 h time point
after LPS treatment (Fig. 4B).
3.4. PTS2 inhibits LPS-increased NO production in RAW264.7
cells
NO is an important inﬂammatory product produced by
iNOS and primarily involves in promoting inﬂammatory re-
sponse [23]. We thus examined the eﬀect of PTS2 on LPS-in-
duced NO release from RAW264.7 cells by detecting changes
of nitrite concentration in cell culture media. The cells were
incubated with 3.0 lM PTS2 for 30 min after pretreatment
with LPS (100 ng/ml).Twelve hours following PTS2 treatment,
the culture media were collected and assayed for nitrite pro-
duction. As shown in Fig. 5, PTS2 signiﬁcantly inhibited
LPS-induced NO release in RAW264.7 cells strongly suggest-
ing an anti-inﬂammatory role of PTS2 in vitro.
Fig. 4. The eﬀects of PTS2 on LPS-induced increase of iNOS protein level time-dependently in RAW264.7 cells. (A) The RAW264.7 cells were
incubated with LPS (100 ng/ml), PTS2 (3.0 lM) or both of them, respectively, for 0–14 h. Cell lysates were prepared and subjected to Western blot
by using anti-iNOS antibody. (B) The RAW264.7 cells were pre-treated with LPS (100 ng/ml) followed by administrating with PTS2 (3.0 lM) after
0.5, 1, 2 or 4 h. Twelve hours following LPS treatment, cell lysates were prepared and subjected to Western blot by using anti-iNOS antibody. The
results were representative of three independent experiments.
Fig. 5. PTS2 inhibits LPS-induced NO production. RAW264.7 cells
were incubated with 3.0 lM PTS2 for 12 h after being pretreated with
LPS (100 ng/ml) for 30 min or not. The culture media were collected
and assayed for nitrite production. The results were representative of
three independent experiments. Data are presented as means ± S.D. **
P < 0.05 compared with the control cells.
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We further evaluated the anti-inﬂammatory activity of PTS2
in the mouse model of endotoxin shock. For examining eﬀects
of PTS2 on septic shock, the mice were administrated with
PTS2 (i.p.) 30 min after LPS (37.5 mg/kg) challenge and mor-
tality was observed. As shown in Fig. 6, 90% mice died from
endotoxin shock during 40 h after the injection (i.p.) of LPS.
PTS2, at dose of 1, 2.5 or 5 mg/kg, raised the survival rate from
10% to 30%, 60% and 90%, respectively, in this animal model
of endotoxin shock (Fig. 6A). To further observe the therapeu-
tic eﬀects of PTS2 on mortality of endotoxin shock, we admin-
istrated mice with 5 mg/kg of PTS2 4 h after LPS treatment.
The data of Fig. 6B indicated that PTS2 raised the survival
rate to 40%.
3.6. PTS2 decreases phosphorylation of STAT1 induced by LPS
Above experiments showed that PTS2 inhibited iNOS but
not COX-2 expression at transcription level (Fig. 3). STAT1has been reported to act as a transcription factor for increasing
iNOS expression under LPS stimulation through binding with
iNOS gene promoter sequence [24], whereas STAT pathway
has a minor role in COX-2 expression [25,26]. In order to ana-
lyse the mechanism of PTS2 in inhibiting LPS-induced iNOS
and COX-2 up-regulation, we further investigated the eﬀect
of PTS2 on STAT1 activation. RAW 246.7 cells were incu-
bated with LPS (100 ng/ml), PTS2 (3.0 lM) or both of them,
respectively, for 2 h or 5 h. The cell lysates were prepared for
Western blot analysis. The results showed that STAT1 phos-
phorylation increased signiﬁcantly in RAW246.7 cells 2 h after
LPS stimulation and maintained at high level for 5 h, whereas
PTS2 inhibited this LPS-induced STAT1 activation (Fig. 7).
The basal level of STAT1 protein was not obviously aﬀected
by LPS and PTS2 treatment (Fig. 7). These results demon-
strated that PTS2 signiﬁcantly suppressed LPS-stimulated
STAT1 phosphorylation, suggesting that PTS2 inhibited
LPS-induced iNOS expression in macrophages by preventing
STAT1 activation.
3.7. PTS2 does not inﬂuence LPS-induced MAPK and NF-jB
activation
It has been well demonstrated that LPS activates MAPKs
including ERK, JNK and p38 as well as NF-jB to produce
various inﬂammatory mediators such as iNOS and COX-2
[27,28]. We thus evaluated the eﬀects of PTS2 on LPS-induced
JNK, ERK and p38 activation in RAW246.7 cells. The cells
were incubated with LPS (100 ng/ml), PTS2 (3.0 lM) or both
of them, respectively, for 0–4 h. Western blot analysis showed
that MAPKs were activated by LPS in a time-dependent man-
ner. Phosphorylation of JNK, ERK and p38 reached maxi-
mum 1 h after LPS stimulation and then gradually
decreased. However, PTS2 did not aﬀect LPS-stimulated
JNK, ERK and p38 activation (Fig. 8). Exposure of cells to
a variety of extracellular stimuli leads to the phosphorylation
and ubiquitination of IjB-a proteins and their degradation
by the proteosome, resulting NF-jB activation [29,30]. We
Fig. 6. PTS2 protects against LPS-induced mortality. (A) Mice were
i.p. injected with saline (h, n = 20), 2.5 mg/kg PTS2 (,, n = 10), 1 mg/
kg PTS2 (h, n = 10), 5 mg/kg PTS2 (n, n = 20) and DEX (s, n =10),
respectively, 30 min after LPS (37.5 mg/kg ) challenge, and the
survival rates were monitored continuously. (B) Mice were i.p. injected
with LPS (37.5 mg/kg) followed by i.p. injecting with 5 mg/kg PTS2
0.5 h (n, n = 20)or 4 h (s, n = 20) after LPS treatment, and the
survival rates were monitored continuously.
Z. Liu et al. / FEBS Letters 582 (2008) 1643–1650 1647then investigated the eﬀect of PTS2 on LPS-stimulated NF-jB
activation in RAW246.7 cells via detecting IjB-a phosphoryla-
tion and degradation by Western blot analysis. The results
showed that PTS2 showed no eﬀect on LPS-induced IjB-a
phosphorylation and degradation (Fig. 9A and B). These data
demonstrated that PTS2 did not inhibit LPS-induced MAPK
and NF-jB activation.Fig. 7. The eﬀects of PTS2 on LPS-induced STAT1 activation. RAW264.7 c
LPS and PTS2, respectively, for 0–5 h. Western blot was performed using a
results were representative of three independent experiments.4. Discussion
Pyrithione (2-mercaptopyridine-1-oxide, PTO) has been
noted for its highly bacteriocidal and fungicidal action for
more than 50 years [31]. Compounds containing a –SH group
are themselves oxidized to generate disulﬁde quickly. For
PTO, such self-oxidation would result in the formation of
the dimmer, dipyrithione (Fig. 1), which itself also possesses
anti-bacterial and anti-fungal activity [32]. However, up till
now, there is no report that demonstrates the anti-inﬂamma-
tory activity of PTS2.
The cascades of events that lead to the highly fatal outcome
of septic shock are believed to be triggered by the entrance of
bacterial wall components, mainly the gram-negative endo-
toxin, into the systemic circulation [33]. A number of agents
including glucocorticoid have been clinical used in terms of
addressing the lethal eﬀects of endotoxin. Glucocorticoids have
been used as anti-inﬂammatory drugs for a long time, but fre-
quent association of serious side eﬀects, such as liver damage,
cancers, stroke, growth stop, have been a long-standing dilem-
ma in clinical steroid anti-inﬂammatory therapy. Non-steroidal
anti-inﬂammatory drugs (NSAIDs) represent one of the most
widely used drug classes including aspirin, indomethacin,
phenylbutazone, etc. Moreover, new anti-inﬂammatory drugs
are being discovered and developed based on their eﬀects on
signal transduction and as anti-cytokine agents [34]. Some pyr-
idine derivates, such as pyroxin and sulfasalazine, have been
known for their anti-inﬂammatory eﬀects. PTS2 is one of the
derivates from pyridine.
It has been well documented that LPS-induced endotoxic
shock represents an adequate tool for understanding inﬂam-
matory processes [35]. The present study demonstrated that
PTS2 is signiﬁcantly eﬀective in protecting mice from LPS-in-
duced lethal shock suggesting its high anti-inﬂammatory activ-
ity. Pro-inﬂammatory cells are among the prime organizers of
systemic inﬂammatory response syndrome and sepsis [36].
There is growing evidence that pro-inﬂammatory cytokines
(e.g., interleukin-1 and tumor necrosis factor a) and mediators
(e.g., NO and PGE2) play critical roles in the development and
perpetuation of tissue inﬂammation and damage [37,38]. NO,
synthesised by iNOS from L-arginine, is well known as an
important mediator of acute and chronic inﬂammation. High
concentration of NO combined with superoxide to form
OONO-peroxynitrite ion which is responsible for severe cell
damage and tissue destruction in inﬂammation. Our result that
PTS2 signiﬁcantly inhibited LPS-induced NO over-production
by reducing iNOS over-expression in RAW246.7 cells demon-
strated the anti-inﬂammatory eﬀects of PTS2 on preventing the
increase of pro-inﬂammatory factors stimulated by endotoxin.ells were incubated with LPS (100 ng/ml) or PTS2 (3.0 lM) or both of
ntibodies to STAT1 and p-STAT1. GAPDH was used as control. The
Fig. 8. The eﬀects of PTS2 on LPS-induced MAPKs activation. RAW264.7 cells were incubated with LPS (100 ng/ml), PTS2 (3.0 lM) or both of
LPS and PTS2, respectively, for 0–4 h. Western blot was performed using antibodies to JNK, p-JNK, p38 MAPK, p-p38, ERK and p-ERK. The
results were representative of three independent experiments.
Fig. 9. The eﬀects of PTS2 on LPS induced NF-jB activation.
RAW264.7 cells were incubated with LPS (100 ng/ml), PTS2 (3.0 lM)
or both of LPS and PTS2 for 1 h. Western blot was performed using
antibodies to p-IjB-a (A), IjB-a (B) and GAPDH. The results were
representative of three independent experiments.
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inﬂammation that causes the pain, fever, swelling, and tender-
ness. COX, has two isoforms, COX-1 and COX-2. Inducible
COX-2 is considered a pro-inﬂammatory enzyme and a target
for the treatment of inﬂammatory diseases. Because COX-2
and iNOS were considered as two important pro-inﬂammatory
enzymes, we also observed the changes of COX-2 after LPS
stimulation and inﬂuence of PTS2. We found that PTS2 also
signiﬁcantly inhibited LPS-induced COX-2 protein increment
in RAW 246.7 cells. These results strongly suggested that
PTS2 could play an important role in protecting against cyto-
toxicity of NO and PGE2 in LPS-induced inﬂammatory re-
sponses and endotoxemia.
In further analysis of the mechanism by which PTS2 inhib-
ited LPS-induced iNOS and COX-2 expression, we found that
though PTS2 decreased the protein level of both iNOS and
COX-2, it suppressed LPS-induced iNOS but not COX-2 genetranscription. This result suggested that PTS2 decreased LPS-
induced iNOS and COX-2 by diﬀerent mechanism. The grow-
ing evidence have indicated that LPS stimulate iNOS and
COX-2 gene expression by triggering MAPK and NF-jB acti-
vation and some inhibitors which block MAPK signaling and
NF-jB activation prevent iNOS and COX-2 expression [39–
41]. Thus, it is not surprised that PTS2 does not aﬀect LPS-in-
duced MAPK and NF-jB activation since it has no eﬀect on
LPS-induced increase of COX-2 mRNA level. As a signal
transducer and activator of transcription, STAT1 could be
phosphorylated on tyrosine residue 701 (Tyr-701) by LPS in
a time-dependent manner [42]. A STAT1-binding GAS site
in mouse iNOS gene promoter was found to be necessary for
full expression of iNOS in LPS-stimulated RAW 264.7 macro-
phages [43]. Targeted disruption of the gene encoding STAT1
resulted in an inability to induce the accumulation of either
protein or mRNA level of iNOS stimulated by LPS in macro-
phages [44]. However, STAT1 just plays a minor role in COX-
2 transcription [25,26]. The results of the present study demon-
strated that PTS2 apparently inhibited LPS-induced activation
of STAT1 in RAW 264.7 macrophages suggesting that the
inhibitory eﬀect of PTS2 on STAT1 activation was a possible
mechanism by which PTS2 suppressed LPS-induced iNOS
but not COX-2 expression at mRNA level.
In response to inﬂammatory stimulation, when iNOS in-
creased COX-2 also increased in a similar pattern [11]. The
interaction of iNOS and COX-2 has been reported. Some
anti-inﬂammatory agents which reducing NO production by
inhibiting the expression of iNOS protein can further decrease
COX-2 expression and activity [12,45]. The iNOS inhibitors
prevent the formation of prostaglandins [46,47]. Furthermore,
iNOS can bind and activate COX-2 [13]. The data from our
study showed that unlike iNOS, LPS-induced COX-2 up-regu-
lation was inhibited by PTS2 only at protein level. These re-
sults combined with the previous reports suggested that
PTS2 might aﬀect COX-2 protein level through altering iNOS
expression.
In summary, our study demonstrated that PTS2 protected
against endotoxic shock in mice and signiﬁcantly inhibited
Z. Liu et al. / FEBS Letters 582 (2008) 1643–1650 1649LPS-induced iNOS expression and NO production in macro-
phages. Meanwhile, PTS2 also reduced LPS-induced increase
of COX-2 protein level. Mechanistically, PTS2 suppressed
iNOS expression through reducing STAT1 phosphorylation
and could possibly reduce LPS-induced increase of COX-2
protein level further. All these data demonstrated a novel
activity of PTS2 in anti-inﬂammatory and provided a possibil-
ity to develop PTS2 as a candidate of anti-inﬂammatory agent
in the future.
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